HeartForce is set to begin the CardioClin study in Ghana aimed at addressing Health Disparities and enhancing Cardiovascular Health in Africa

This investigational study will examine the potential of the EMR-score specifically for Black African populations. The results may lead to: • Customized Cardiovascular Screening: Developing a validated and effective tool for the early detection of coronary artery disease (CAD) tailored to Black Africans. • Increased Accuracy: Focusing on genetic, environmental, and lifestyle factors specific to… Continue reading HeartForce is set to begin the CardioClin study in Ghana aimed at addressing Health Disparities and enhancing Cardiovascular Health in Africa

Published
Categorized as news

Heart Force is excited to announce the successful completion of its Pre- and Post-Stent clinical study in Uzbekistan

Our research focused on monitoring patients after stent procedures, paving the way for improved patient care for heart patients following their procedures. The findings confirm that the vibration signal recorded prior to stent placement can serve as a reliable indicator for post-procedure monitoring. Key takeaways include: • Predictive Monitoring: The vibration signal captured before the… Continue reading Heart Force is excited to announce the successful completion of its Pre- and Post-Stent clinical study in Uzbekistan

Published
Categorized as news

Integration of the EMR-Score into the CardioClin Platform

HeartForce has successfully integrated its advanced EMR-Score algorithm portfolio into the CardioClin platform. This move positions CardioClin as the leading early detection tool for coronary artery disease (CAD), primarily assisting physicians and nurses. We are now ready to seek regulatory approvals from Health Canada, and the FDA. The improved EMR-Score uses both qualitative and quantitative… Continue reading Integration of the EMR-Score into the CardioClin Platform

Published
Categorized as news

Design Freeze for CardioClin 3.0

The recent design freeze for CardioClin marks an important milestone for HeartForce in advancing towards commercialization and regulatory approval. Following extensive clinical research involving over 4,000 patients and valuable input from healthcare experts, the latest iteration of CardioClin has undergone meticulous redesign to improve its user-friendliness and features. Additionally, our exclusive core technology has been… Continue reading Design Freeze for CardioClin 3.0

Published
Categorized as news

HeartForce Commences Production of 200 CardioClin’s for Testing Purposes

The manufacturing process for 200 CardioClin devices for testing purposes has commenced. HeartForce has started producing 200 units of the CardioClin version 3.0, which features a new compact and seamless design. These devices will be sent to key opinion leaders in Canada, Germany, and Switzerland. Each device will come with 20 patches and an additional… Continue reading HeartForce Commences Production of 200 CardioClin’s for Testing Purposes

Published
Categorized as news

Completion of Statistical Analysis for Cost-Effectiveness report

HeartForce has finalized its analysis on the cost-effectiveness of the CardioClin within the Canadian healthcare system. By analyzing billing codes under the Ontario Health Insurance Plan (OHIP), we investigated the devices utilized in the diagnostic pathway for Coronary Artery Disease (CAD). This pathway encompasses both the bulk of individuals diagnosed with CAD and, those with… Continue reading Completion of Statistical Analysis for Cost-Effectiveness report

Published
Categorized as news

EMR Score Introduced at the Computing in Cardiology Conference

HeartForce introduced the Electromechanical Risk (EMR) Score at the prestigious CinC2023 conference held in Atlanta. Computing in Cardiology Conference, a globally recognized scientific symposium, provides a platform for experts in the fields of medicine, physics, engineering, and computer science to disseminate their cutting-edge research in clinical cardiology and cardiovascular physiology. The EMR Score’s debut at… Continue reading EMR Score Introduced at the Computing in Cardiology Conference

Published
Categorized as news

HeartForce presents CardioClin 3.0

Hearforce’s design team optimized the next generation of CardioClin which featured a more ergonomic shape and improved usability. The narrower shape allows a better fit for both female and male users. The small disposable electrode patch lets the sensor be easy to apply and sanitize.

Published
Categorized as news

Finalization of HeartForce proprietary EMR-Score-Algorithm

HeartForce has developed the Electromechanical Risk (EMR) Score, a groundbreaking AI-powered tool for precise cardiac risk assessment in coronary artery disease (CAD) screening. Leveraging seismocardiography (SCG) data and clinical variables, the EMR Score offers a non-invasive, data-driven approach to screen CAD risk. The use of SCG enhances patient comfort and convenience during screening. The EMR… Continue reading Finalization of HeartForce proprietary EMR-Score-Algorithm

Published
Categorized as news

Finalizing AFib Algorithm

Heartforce’s Afib detection algorithm was tested on a large database of 84k cases with an accuracy equivalent to current FDA approved algorithms. Afib detection will be deployed on future CardioClin and CardioPro products and will be ready for Health Canada and FDA submissions.

Published
Categorized as news

HeartForce starts Phase 1 of Verification Study in Uzbekistan

HeartForce has embarked on Phase 1 of a Verification Study in Uzbekistan. This significant undertaking follows the successful development of the EMR Score in a prior study. In this new phase, HeartForce is in the process of acquiring a comprehensive verification database, meticulously designed to closely resemble the characteristics of the actual target population. This… Continue reading HeartForce starts Phase 1 of Verification Study in Uzbekistan

Published
Categorized as news

HeartForce files new provisional patent in the US

HeartForce filed a patent application in the United States for monitoring patients after coronary angioplasty.  The provisional patent was assigned the application number U.S. 63/459960.  Meanwhile, the company will be conducting a one-year clinical study through the monitoring patients pre and post stent surgery

Published
Categorized as news

Fifth HeartForce Update on the CardioClin Multi-Center Study in Uzbekistan

HeartForce is proud to announce that it has successfully completed the entire data collection process in Uzbekistan consisting of: (1) patients with high levels of coronary artery disease (Stenosis of ≥ 50% in at least one coronary artery), (2) a healthy and age-matched control group and (3) patients with mild to medium levels of occlusion… Continue reading Fifth HeartForce Update on the CardioClin Multi-Center Study in Uzbekistan

Published
Categorized as news

HeartForce files Continuation of United States Patent Application

HeartForce has successfully filed a continuation application at the United States Patent and Trademark Office on November 21, 2022: “Sensor apparatuses, methods of operating same and systems including same and methods and systems for sensing and analyzing electromechanical characteristics of a heart” In accordance with our instructions, the continuation application was assigned application number 17/991,523.… Continue reading HeartForce files Continuation of United States Patent Application

Published
Categorized as news

Fourth HeartForce Update on the Cardio Clin Multi-Center Study in Uzbekistan

HeartForce’s scientific team in Uzbekistan has collected in-depth data for developing an algorithm to screen for coronary artery disease (CAD). The study has been divided into three phases. In phase 1, we collected a total of 1,530 patients’ data to investigate the ability to use machine learning algorithms to predict the presence of CAD. Most… Continue reading Fourth HeartForce Update on the Cardio Clin Multi-Center Study in Uzbekistan

Published
Categorized as news

HeartForce Commences Automatic Improvement of ECG Processing Methods

The objective of our study is to enhance the accuracy of the Q-wave detection to handle abnormal ECG signal patterns more accurately. Q-wave detection is a significant factor for segmenting the cardiac vibrational signal for coronary artery disease (CAD) detection. By identifying the abnormal ECG signal segment (e.g., caused by Afib, premature contraction, movement artifacts,… Continue reading HeartForce Commences Automatic Improvement of ECG Processing Methods

Published
Categorized as news

HeartForce Introduces CardioClin 2.0

In spring of 2022, our development team updated the design of our CardioClin for improved user ergonomics. The new design has an inverted heart shape which is attached to the sternum using a standard ECG adhesive electrode. It has two ports for the “right-arm” and “left-leg” ECG leads. A light indicator is located on the… Continue reading HeartForce Introduces CardioClin 2.0

Published
Categorized as news

Third HeartForce Update on the CardioClin Multi-Center Study in Uzbekistan

As reported in November of 2021, HeartForce has successfully completed the data collection of 1500 patients, suspected of having coronary artery disease (CAD), in the clinical trial in Uzbekistan. The dataset consisted of the following two datasets: Tashkent Patients and Karshi Patients Tashkent Control Group The first data set consisted of patients that were suspected… Continue reading Third HeartForce Update on the CardioClin Multi-Center Study in Uzbekistan

Published
Categorized as news